In addition to standard ADT, which patients with hormone-sensitive metastatic prostate cancer should receive abiraterone, docetaxel, both, or neither?
Journal of Clinical Oncology
Original Article: First-Line Treatment of Hormone-Sensitive Metastatic PCa